ImmuCell Corporation Reports Narrowing Net Loss in 2025 Amid Sales and Margin Growth

ImmuCell Corporation reported a narrowed net loss of $1 million in 2025, up from $2.2 million in 2024. Product sales increased 4.3% to $27.6 million, with gross margin expanding to 41.4% from 30%. Operating income improved to $1.6 million, and the company ended the year with $3.8 million in cash and cash equivalents. Management characterized 2025 as a successful year, marked by operational improvements and strategic changes.